

Joint Working

Executive Summary

Project title	A community anticoagulant service for the frail patient population; a 12 months pilot project. Hence reducing the protect and perfect gap.
Project partners	University Hospital Birmingham NHS Foundation Trust – Heartlands Hospital
Start date	July 2020

Project summary

There are a number of AF patients in Birmingham/Solihull who are either exempted patients, who have been diagnosed AF but deemed too risky to be anticoagulated by their GP or who are inadequately anticoagulated. These patients are not currently seen in any anticoagulant service setting simply because there is no referral pathway for them. This project seeks to improve care of the frail elderly patients anticoagulation exempted or sub-optimally anticoagulated patients who will get a domiciliary review with an Advanced Clinical Practitioner covering the reason for exemption, medical history, frailty assessment and blood tests. This will address and improve diagnosis and management of Atrial Fibrillation in the frail and elderly. Hence reducing the protect and perfect gap of patients commencing on anticoagulation.

Expected benefits to patients and the NHS & Daiichi-Sankyo

Expected Benefits for the Patient:

- The benefit to the frail and elderly patient is a domiciliary review/care closer to home
- To potentially reduce the risk of stroke by treating with OAC
- Improved efficacy rates by the optimisation of OAC's.
- Patients who are considered to be too risky to be offered anticoagulants will be identified and their GP informed formally

Expected Benefits for the Organisation:

- Enhance the Trust's target to reduce the amount of admissions for falls
- Offer a state of the art specialised anticoagulation service for frail patients
- Improve UHB anticoagulation service reputation nationally

Expected Benefits for Daiichi-Sankyo UK:

- Improve Daiichi-Sankyo's reputational profile amongst local and national stakeholders and expand its joint working portfolio.
- Create more opportunities for the appropriate use of Direct Oral Anticoagulants, including Daiichi- Sankyo UK's medicines in suitable patients in line with NICE treatment guidelines. If this improvement occurs, we are likely to see an increase in DOAC prescriptions.